Humacyte, Inc. (HUMA)

NASDAQ: HUMA · IEX Real-Time Price · USD
0.02 (0.43%)
At close: May 20, 2022 4:00 PM
0.20 (4.25%)
After-hours:May 20, 2022 5:13 PM EDT

Company Description

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection.

The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes.

The company was founded in 2004 and is headquartered in Durham, North Carolina.

Humacyte, Inc.
CountryUnited States
SectorHealth Care

Contact Details

2525 East North Carolina Highway 54
Durham, NC 27713
United States
Phone919 313 9633

Stock Details

Ticker SymbolHUMA
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code1818382

Key Executives

Dr. Laura E. Niklason M.D., Ph.D.Founder, President, Chief Executive Officer and Director
Dale A. SanderChief Financial Officer, Chief Corporate Development Officer and Treasurer
Dr. Heather Ledbetter Prichard Ph.D.Chief Operating Officer
Dr. Juliana L. Blum Ph.D.Co-Founder and Executive Vice President of Corporate Development
Sabrina OsborneExecutive Vice President of Business Strategy and People
William Edward Tente M.S, M.S.Chief Regulatory Officer
William ScheesseleChief Commercial Officer
Dr. Shamik J. Parikh M.D.Chief Medical Officer

Latest SEC Filings

May 18, 20224Statement of changes in beneficial ownership of securities
May 13, 2022424B3Prospectus [Rule 424(b)(3)]
May 13, 202210-QQuarterly report [Sections 13 or 15(d)]
May 13, 20228-KCurrent report
Apr 29, 2022DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2022DEF 14AOther definitive proxy statements
Apr 5, 20224Statement of changes in beneficial ownership of securities
Apr 5, 20223Initial statement of beneficial ownership of securities
Apr 4, 2022424B7Prospectus [Rule 424(b)(7)]
Apr 1, 2022EFFECTNotice of Effectiveness
View All SEC Filings